CLINUVEL

ASX ANNOUNCEMENT

Melbourne, Australia, 22 April 2024

ASX: CUV | **Börse Frankfurt**: UR9 | **ADR Level 1**: CLVLY

CLINUVEL expands global leadership team

CLINUVEL today announced the appointment of two industry professionals to its leadership team. Dr Emilie Rodenburger has rejoined the Group as Director, Global Clinical Affairs, with Myles Clouston taking on the newly established role of Head of US Investor Relations.

Clinical leadership team

A pharmacist (PharmD) with a master's degree in cancer biology, Dr Rodenburger previously worked with the CLINUVEL Group for over a decade in clinical development roles in Australia, the USA and Europe. During this time, she led the Company's first vitiligo trials as well as being one of two clinical managers completing the EPP[1] program resulting in the successful approval and commercialisation of SCENESSE® (afamelanotide) as the first systemic photoprotective therapy. Dr Rodenburger spent four years with Roche in senior clinical roles.

Based in the UK, Dr Rodenburger will oversee CLINUVEL's global clinical program, evaluating melanocortin-based drugs for a range of disorders of the skin and brain. Her immediate focus will be to ensure full enrolment and analyses of the CUV105 study of SCENESSE® in vitiligo (loss of pigmentation).

Investor relations

Mr Clouston joins in a newly created role, with a focus on increasing CLINUVEL's profile in the US market. Based in New York, Mr Clouston has extensive capital markets experience. This includes an extended period with Nasdaq on its global advisory leadership team, and working across life sciences, most recently with Xilio Therapeutics (Nasdaq:XLO), and previously with MorphoSys (ETR:MOR) and Mylan (now Nasdaq:VTRS). With Mr Clouston, CLINUVEL now carries a comprehensive IR team to increase its visibility.

Commentary

"Part of our ambition to grow the Company longer term is to evolve and strengthen the senior and executive management team," CLINUVEL's CEO, Dr Philippe Wolgen said. *"The return of Dr Rodenburger in a leadership role indicates how CLINUVEL has cultivated a unique foundation and culture where talented professionals can fulfil their long-term ambitions. Dr Rodenburger, together with Drs Bilbao and Teng, will complete the vitiligo program and prepare the North American distribution network.*

"In aiming to expand our shareholder base and global prominence as a successful biopharmaceutical, we are dedicating internal resources towards Australia, Europe, and North America. We now have three IR managers working in concert, with Mr Clouston bringing a complementary skill set and institutional focus to the US market. Coordination of a global IR program will increase the Company's exposure, articulating a value proposition differentiating it from its peers," Dr Wolgen said.

– END –

1 Erythropoietic protoporphyria

About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL (ASX: CUV; ADR LEVEL 1: CLVLY; Börse Frankfurt: UR9) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare

solutions for specialised populations. As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, assisted DNA repair, repigmentation and acute or life-threatening conditions who lack alternatives.

CLINUVEL's lead therapy, SCENESSE® (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the world's first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information, please go to https://www.clinuvel.com.

Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD.

Head of Investor Relations

Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

Investor Enquiries

https://www.clinuvel.com/investors/contact-us

Forward-Looking Statements

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products; the COVID-19 pandemic and/or other world, regional or national events affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE® (afamelanotide 16mg), PRÉNUMBRA® or NEURACTHEL®; our ability to achieve expected safety and efficacy results in a timely manner through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, Israel, China and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE®, PRÉNUMBRA® or NEURACTHEL® which may lead to it being unable to supply its commercial markets and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology and consumer based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; our ability to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2023 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on preliminary and uncertain forecasts and estimates is available on request, whereby it is stated that past performance is not an indicator of future performance.

Contact:

Tel: +61 3 9660 4900
Fax: +61 3 9660 4909
Email: mail@clinuvel.com
Australia (Head Office), Level 22, 535 Bourke Street, Melbourne, Victoria, 3000, Australia